Category: 1375301-91-9

Zhang, Chao published the artcileRAF inhibitors that evade paradoxical MAPK pathway activation, Application In Synthesis of 1375301-91-9, the publication is Nature (London, United Kingdom) (2015), 526(7574), 583-586, database is CAplus and MEDLINE.

Oncogenic activation of BRAF fuels cancer growth by constitutively promoting RAS-independent mitogen-activated protein kinase (MAPK) pathway signalling. Accordingly, RAF inhibitors have brought substantially improved personalized treatment of metastatic melanoma. However, these targeted agents have also revealed an unexpected consequence: stimulated growth of certain cancers. Structurally diverse ATP-competitive RAF inhibitors can either inhibit or paradoxically activate the MAPK pathway, depending whether activation is by BRAF mutation or by an upstream event, such as RAS mutation or receptor tyrosine kinase activation. Here we have identified next-generation RAF inhibitors (dubbed ‘paradox breakers’) that suppress mutant BRAF cells without activating the MAPK pathway in cells bearing upstream activation. In cells that express the same HRAS mutation prevalent in squamous tumors from patients treated with RAF inhibitors, the first-generation RAF inhibitor vemurafenib stimulated in vitro and in vivo growth and induced expression of MAPK pathway response genes; by contrast the paradox breakers PLX7904 and PLX8394 had no effect. Paradox breakers also overcame several known mechanisms of resistance to first-generation RAF inhibitors. Dissociating MAPK pathway inhibition from paradoxical activation might yield both improved safety and more durable efficacy than first-generation RAF inhibitors, a concept currently undergoing human clin. evaluation with PLX8394.

Nature (London, United Kingdom) published new progress about 1375301-91-9. 1375301-91-9 belongs to pyrimidines, auxiliary class Pyrimidine,Boronic acid and ester,Boronate Esters,Boronic acid and ester, name is 2-Cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine, and the molecular formula is C10H9NO, Application In Synthesis of 1375301-91-9.

Referemce:
https://pubchem.ncbi.nlm.nih.gov/compound/Pyrimidine,
Pyrimidine – Wikipedia

Zhao, Jichen published the artcileHighly Selective MERTK Inhibitors Achieved by a Single Methyl Group, HPLC of Formula: 1375301-91-9, the publication is Journal of Medicinal Chemistry (2018), 61(22), 10242-10254, database is CAplus and MEDLINE.

Although all kinases share the same ATP binding pocket, subtle differences in the residues that form the pocket differentiate individual kinases’ affinity for ATP competitive inhibitors. The authors have found that by introducing a single Me group, the selectivity of the MERTK inhibitors over another target, FLT3, was increased up to 1000-fold (compound I). Compound II was identified as an in vivo tool compound with subnanomolar activity against MERTK and 38-fold selectivity over FLT3 in vitro. The potency and selectivity of II for MERTK over FLT3 were confirmed in cell-based assays using human cancer cell lines. Compound II had favorable pharmacokinetic properties in mice. Phosphorylation of MERTK was decreased by 75% in bone marrow leukemia cells from mice treated with II compared to vehicle-treated mice.

Journal of Medicinal Chemistry published new progress about 1375301-91-9. 1375301-91-9 belongs to pyrimidines, auxiliary class Pyrimidine,Boronic acid and ester,Boronate Esters,Boronic acid and ester, name is 2-Cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine, and the molecular formula is C5H6N2O2, HPLC of Formula: 1375301-91-9.

Referemce:
https://pubchem.ncbi.nlm.nih.gov/compound/Pyrimidine,
Pyrimidine – Wikipedia